Bevacizumab in ovarian cancer: A critical review of phase III studies

Bevacizumab (BV) is a humanized monoclonal antibody targeting vascular endothelial growth factor and it is the first molecular-targeted agent to be used for the treatment of ovarian cancer (OC). Randomized Phase III trials evaluated the combination of BV plus standard chemotherapy for first-line tre...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Rossi, Luigi, Verrico, Monica, Zaccarelli, Eleonora, Papa, Anselmo, Colonna, Maria, Strudel, Martina, Vici, Patrizia, Bianco, Vincenzo, Tomao, Federica
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2016
Teme:
Review
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5355353/
https://ncbi.nlm.nih.gov/pubmed/27852039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13310
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki